Published in J Alzheimers Dis on August 01, 2008
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med (2012) 2.39
The role of tau kinases in Alzheimer's disease. Curr Opin Drug Discov Devel (2010) 1.15
The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. Neurobiol Dis (2010) 1.12
The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev (2013) 1.05
Are tangles as toxic as they look? J Mol Neurosci (2011) 1.05
NMNAT suppresses tau-induced neurodegeneration by promoting clearance of hyperphosphorylated tau oligomers in a Drosophila model of tauopathy. Hum Mol Genet (2011) 1.02
Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci (2012) 1.02
Electrophysiological changes precede morphological changes to frontal cortical pyramidal neurons in the rTg4510 mouse model of progressive tauopathy. Acta Neuropathol (2012) 0.99
The protein phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif also recognized by the kinase Fyn: implications for tauopathies. J Biol Chem (2012) 0.96
SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci U S A (2014) 0.90
Pericellular innervation of neurons expressing abnormally hyperphosphorylated tau in the hippocampal formation of Alzheimer's disease patients. Front Neuroanat (2010) 0.87
Relationship between tau pathology and neuroinflammation in Alzheimer's disease. Mt Sinai J Med (2010) 0.86
Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination. Nat Neurosci (2015) 0.84
The Beta-amyloid protein of Alzheimer's disease: communication breakdown by modifying the neuronal cytoskeleton. Int J Alzheimers Dis (2013) 0.82
A new coumarin derivative, IMM-H004, attenuates okadaic acid-induced spatial memory impairment in rats. Acta Pharmacol Sin (2016) 0.75
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Observations on the brains of demented old people. J Neurol Sci (1970) 6.99
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem (1986) 6.91
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science (1991) 5.60
Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol (1998) 5.42
Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem (1984) 3.36
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 2.97
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2.46
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem (1993) 2.30
Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem (1992) 2.04
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A (1997) 1.73
Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol (1999) 1.69
Granular tau oligomers as intermediates of tau filaments. Biochemistry (2007) 1.67
Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol (2003) 1.66
Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol (2003) 1.64
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem (2004) 1.58
Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res (2006) 1.49
The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J Biol Chem (2007) 1.37
Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A (2006) 1.33
Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem (1995) 1.32
Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res Mol Brain Res (1996) 1.30
Identification and localization of a tau peptide to paired helical filaments of Alzheimer disease. Proc Natl Acad Sci U S A (1989) 1.29
Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem (2001) 1.28
Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett (1994) 1.27
Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (1987) 1.22
Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J Cell Mol Med (2007) 1.21
Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol (2007) 1.11
Alzheimer paired helical filaments. Restoration of the biological activity by dephosphorylation. FEBS Lett (1994) 1.04
Identification and isolation of a hyperphosphorylated, conformationally changed intermediate of human protein tau expressed in yeast. Biochemistry (2005) 0.95
Tau and ubiquitin immunoreactivity at different stages of formation of Alzheimer neurofibrillary tangles. Prog Clin Biol Res (1989) 0.91
P70 S6 kinase mediates tau phosphorylation and synthesis. FEBS Lett (2005) 0.89
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.67
Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta (2005) 2.46
Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci (2005) 2.35
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24
Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem (2005) 1.64
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol (2011) 1.63
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem (2004) 1.58
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain (2009) 1.48
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J (2008) 1.43
Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis (2013) 1.40
Failure of neuronal maturation in Alzheimer disease dentate gyrus. J Neuropathol Exp Neurol (2008) 1.39
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol (2005) 1.37
Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci (2007) 1.36
Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A (2006) 1.33
Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer's disease. Brain Res Mol Brain Res (2002) 1.27
Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta. FEBS Lett (2002) 1.26
Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem (2004) 1.24
Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol (2002) 1.22
Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett (2008) 1.22
Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome. J Biol Chem (2008) 1.22
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
Trophic factors counteract elevated FGF-2-induced inhibition of adult neurogenesis. Neurobiol Aging (2006) 1.21
Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer's disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis (2001) 1.20
Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem (2010) 1.16
Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr Alzheimer Res (2008) 1.14
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers. Ann Neurol (2005) 1.14
Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol (2002) 1.14
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett (2004) 1.13
PKA modulates GSK-3beta- and cdk5-catalyzed phosphorylation of tau in site- and kinase-specific manners. FEBS Lett (2006) 1.12
Disruption of microtubule network by Alzheimer abnormally hyperphosphorylated tau. Acta Neuropathol (2007) 1.11
Anesthesia induces phosphorylation of tau. J Alzheimers Dis (2009) 1.11
Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2(PP2A)/SET. FEBS Lett (2011) 1.10
The dentate gyrus neurogenesis: a therapeutic target for Alzheimer's disease. Acta Neuropathol (2002) 1.10
Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J Neurochem (2007) 1.10
Okadaic-acid-induced inhibition of protein phosphatase 2A produces activation of mitogen-activated protein kinases ERK1/2, MEK1/2, and p70 S6, similar to that in Alzheimer's disease. Am J Pathol (2003) 1.10
Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem (2009) 1.08
PP2A regulates tau phosphorylation directly and also indirectly via activating GSK-3beta. J Alzheimers Dis (2010) 1.06
Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol (2010) 1.05
Inhibitors of protein phosphatase-2A from human brain structures, immunocytological localization and activities towards dephosphorylation of the Alzheimer type hyperphosphorylated tau. FEBS Lett (2005) 1.05
Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. J Alzheimers Dis (2006) 1.05
Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett (2002) 1.04
Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer disease. FASEB J (2007) 1.04
Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem (2009) 1.03
The carboxy-terminal fragment of inhibitor-2 of protein phosphatase-2A induces Alzheimer disease pathology and cognitive impairment. FASEB J (2010) 1.02
An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol (2011) 1.02
Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathol (2005) 0.99
Alzheimer's disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement (2010) 0.99
Assessments of the accumulation severities of amyloid beta-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains. Neurobiol Dis (2006) 0.97
Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5. J Neurochem (2004) 0.97
Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett (2006) 0.97
Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett (2002) 0.97
Dysregulation of protein phosphorylation/dephosphorylation in Alzheimer's disease: a therapeutic target. J Biomed Biotechnol (2006) 0.96
I1PP2A affects tau phosphorylation via association with the catalytic subunit of protein phosphatase 2A. J Biol Chem (2008) 0.95
Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A. Nucleic Acids Res (2011) 0.95
Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease. J Biol Chem (2004) 0.95
Enhancement of dentate gyrus neurogenesis, dendritic and synaptic plasticity and memory by a neurotrophic peptide. Neurobiol Aging (2009) 0.95
Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease. J Biol Chem (2013) 0.94
Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective. J Alzheimers Dis (2006) 0.93
Inhibitors of protein phosphatase-2A: topography and subcellular localization. Brain Res Mol Brain Res (2004) 0.93
Targeting tau protein in Alzheimer's disease. Drugs Aging (2010) 0.92
Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis (2009) 0.92
Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci U S A (2014) 0.92
Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One (2012) 0.91
A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol (2012) 0.91
Blood-cerebrospinal fluid barrier permeability in Alzheimer's disease. J Alzheimers Dis (2011) 0.91
Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. J Cell Sci (2004) 0.91
Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity is increased in Alzheimer disease. Clin Chem (2009) 0.90
Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain. PLoS One (2012) 0.90
Decrease of protein phosphatase 2A and its association with accumulation and hyperphosphorylation of tau in Down syndrome. J Alzheimers Dis (2008) 0.90
Tau in cerebrospinal fluid: a sensitive sandwich enzyme-linked immunosorbent assay using tyramide signal amplification. Neurosci Lett (2007) 0.89
Rescue of synaptic failure and alleviation of learning and memory impairments in a trisomic mouse model of down syndrome. J Neuropathol Exp Neurol (2011) 0.89
Inhibition of protein phosphatase 2A induces phosphorylation and accumulation of neurofilaments in metabolically active rat brain slices. Neurosci Lett (2003) 0.89
Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: a mechanism involved in tau pathology of Alzheimer disease. J Biol Chem (2011) 0.89
Elevation of the level and activity of acid ceramidase in Alzheimer's disease brain. Eur J Neurosci (2004) 0.89
Up-regulation of cell division cycle (cdc) 2 kinase in neurons with early stage Alzheimer's disease neurofibrillary degeneration. Acta Neuropathol (2002) 0.89
Activation of protein phosphatase 2B and hyperphosphorylation of Tau in Alzheimer's disease. J Alzheimers Dis (2011) 0.88
Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna) (2014) 0.87
Regulation of phosphorylation of tau by protein kinases in rat brain. Neurochem Res (2006) 0.87
Regulation of alternative splicing of tau exon 10 by 9G8 and Dyrk1A. Neurobiol Aging (2011) 0.87
Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J Mol Neurosci (2002) 0.87
Phosphothreonine-212 of Alzheimer abnormally hyperphosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem Res (2005) 0.86
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion. J Biol Chem (2012) 0.86
Brain gene expression of a sporadic (icv-STZ Mouse) and a familial mouse model (3xTg-AD mouse) of Alzheimer's disease. PLoS One (2012) 0.86
Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease. J Alzheimers Dis (2008) 0.85
Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. J Alzheimers Dis (2010) 0.85
CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease. Nucleic Acids Res (2013) 0.85
Tau-induced neurodegeneration: mechanisms and targets. Neurosci Bull (2014) 0.84
Pharmacological approaches of neurofibrillary degeneration. Curr Alzheimer Res (2005) 0.84
Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection. Acta Neuropathol (2013) 0.84
Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures. PLoS One (2013) 0.84
Novel therapeutic strategies for neurodegenerative disease. Psychogeriatrics (2009) 0.83
Effect of melatonin and melatonylvalpromide on beta-amyloid and neurofilaments in N2a cells. Neurochem Res (2008) 0.83
Splicing factor SC35 promotes tau expression through stabilization of its mRNA. FEBS Lett (2011) 0.83
Alzheimer's disease neurofibrillary degeneration: pivotal and multifactorial. Biochem Soc Trans (2010) 0.82
Alzheimer neurofibrillary degeneration: therapeutic targets and high-throughput assays. J Mol Neurosci (2003) 0.82
Opportunities and challenges in developing Alzheimer disease therapeutics. Acta Neuropathol (2011) 0.82
Bilateral injection of isoproterenol into hippocampus induces Alzheimer-like hyperphosphorylation of tau and spatial memory deficit in rat. FEBS Lett (2005) 0.81